Why the Japan Neurology Clinical Trials Market Is Set to Nearly Double by 2034 — and What It Means for Pharma Leaders Targeting Japan Japan's aging population is driving one of the most closely watched neurology research pipelines in Asia, as domestic and global drugmakers race to bring new Alzheimer's and Parkinson's therapies through the country's fast-track regulatory system....

Why the Neurology Clinical Trials Market Is Set to Nearly Double by 2034 — and What It Means for Pharma and CRO Leaders Alzheimer's, Parkinson's, and stroke are affecting a growing share of an aging global population, and the search for effective treatments is intensifying at a pace few other therapeutic areas can match. According to Polaris Market Research, the global Neurology Clinical...

Why the U.S. Neurology Clinical Trials Market Is Set to Nearly Double by 2034 — and What It Means for Pharma and CRO Leaders With roughly 7 million Americans living with Alzheimer's disease alone, the pressure to bring new neurological therapies to market has rarely been higher — and the U.S. research infrastructure built to support that effort keeps expanding. According to Polaris...